Europe
Biopharma and life sciences companies from across the globe provide updates on their business and pipelines.
Olorofim is in a Phase IIb study that focuses on rare and resistant life-threatening invasive fungal infections, such as invasive aspergillosis (including azole-resistant strains), scedosporiosis, lomentosporiosis, fusariosis, scopulariopsosis and coccidioidomycosis.
Celleron Therapeutics signed a licensing agreement with Roche for the worldwide rights to cancer drug emactuzumab, a monoclonal antibody directed against colony-stimulating factor 1 (CSF-1R) expressed on macrophages.
The government of Russia has approved a vaccine for COVID-19, marking the first preventative treatment for the novel coronavirus.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 12, 2020.
With a $425 million upfront payment, Bayer bolstered its women’s healthcare pipeline with the acquisition of U.K.-based KaNDy Therapeutics and its investigational treatment for menopause.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 10, 2020.
Intravenous immunoglobulin (IVIG) could be a key to combating seriously ill COVID-19 patients who have been hospitalized due to complications from the disease, and Octapharma AG aims to find out as it assesses the plasma-based treatment in a Phase III study.
Biopharma and life sciences companies strengthen their leadership teams and board with these Movers and Shakers.
It was a moderately busy week for clinical trial news, with some particularly interesting announcements related COVID-19 vaccine trials. Here’s a look.
PRESS RELEASES